KMDA
Price
$6.67
Change
-$0.02 (-0.30%)
Updated
Sep 26 closing price
Capitalization
383.71M
45 days until earnings call
RDY
Price
$14.22
Change
+$0.06 (+0.42%)
Updated
Sep 26 closing price
Capitalization
11.75B
26 days until earnings call
Interact to see
Advertisement

KMDA vs RDY

Header iconKMDA vs RDY Comparison
Open Charts KMDA vs RDYBanner chart's image
Kamada
Price$6.67
Change-$0.02 (-0.30%)
Volume$66.65K
Capitalization383.71M
Dr. Reddy's Laboratories
Price$14.22
Change+$0.06 (+0.42%)
Volume$1.21M
Capitalization11.75B
KMDA vs RDY Comparison Chart in %
Loading...
KMDA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RDY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
KMDA vs. RDY commentary
Sep 28, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is KMDA is a StrongBuy and RDY is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 28, 2025
Stock price -- (KMDA: $6.67 vs. RDY: $14.22)
Brand notoriety: KMDA and RDY are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: KMDA: 136% vs. RDY: 112%
Market capitalization -- KMDA: $383.71M vs. RDY: $11.75B
KMDA [@Pharmaceuticals: Generic] is valued at $383.71M. RDY’s [@Pharmaceuticals: Generic] market capitalization is $11.75B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $63.66B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.82B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

KMDA’s FA Score shows that 0 FA rating(s) are green whileRDY’s FA Score has 0 green FA rating(s).

  • KMDA’s FA Score: 0 green, 5 red.
  • RDY’s FA Score: 0 green, 5 red.
According to our system of comparison, RDY is a better buy in the long-term than KMDA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

KMDA’s TA Score shows that 3 TA indicator(s) are bullish while RDY’s TA Score has 5 bullish TA indicator(s).

  • KMDA’s TA Score: 3 bullish, 4 bearish.
  • RDY’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, both KMDA and RDY are a bad buy in the short-term.

Price Growth

KMDA (@Pharmaceuticals: Generic) experienced а -3.47% price change this week, while RDY (@Pharmaceuticals: Generic) price change was -4.37% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -1.16%. For the same industry, the average monthly price growth was +24.25%, and the average quarterly price growth was +66.99%.

Reported Earning Dates

KMDA is expected to report earnings on Nov 12, 2025.

RDY is expected to report earnings on Oct 24, 2025.

Industries' Descriptions

@Pharmaceuticals: Generic (-1.16% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RDY($11.7B) has a higher market cap than KMDA($384M). KMDA has higher P/E ratio than RDY: KMDA (20.84) vs RDY (18.54). KMDA YTD gains are higher at: 12.662 vs. RDY (-9.379). RDY has higher annual earnings (EBITDA): 98.1B vs. KMDA (34.2M). RDY has more cash in the bank: 66.7B vs. KMDA (66M). KMDA has less debt than RDY: KMDA (11.4M) vs RDY (48.6B). RDY has higher revenues than KMDA: RDY (334B) vs KMDA (170M).
KMDARDYKMDA / RDY
Capitalization384M11.7B3%
EBITDA34.2M98.1B0%
Gain YTD12.662-9.379-135%
P/E Ratio20.8418.54112%
Revenue170M334B0%
Total Cash66M66.7B0%
Total Debt11.4M48.6B0%
FUNDAMENTALS RATINGS
KMDA vs RDY: Fundamental Ratings
KMDA
RDY
OUTLOOK RATING
1..100
8470
VALUATION
overvalued / fair valued / undervalued
1..100
70
Overvalued
77
Overvalued
PROFIT vs RISK RATING
1..100
10050
SMR RATING
1..100
7852
PRICE GROWTH RATING
1..100
6059
P/E GROWTH RATING
1..100
4054
SEASONALITY SCORE
1..100
8550

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

KMDA's Valuation (70) in the Biotechnology industry is in the same range as RDY (77) in the Pharmaceuticals Generic industry. This means that KMDA’s stock grew similarly to RDY’s over the last 12 months.

RDY's Profit vs Risk Rating (50) in the Pharmaceuticals Generic industry is somewhat better than the same rating for KMDA (100) in the Biotechnology industry. This means that RDY’s stock grew somewhat faster than KMDA’s over the last 12 months.

RDY's SMR Rating (52) in the Pharmaceuticals Generic industry is in the same range as KMDA (78) in the Biotechnology industry. This means that RDY’s stock grew similarly to KMDA’s over the last 12 months.

RDY's Price Growth Rating (59) in the Pharmaceuticals Generic industry is in the same range as KMDA (60) in the Biotechnology industry. This means that RDY’s stock grew similarly to KMDA’s over the last 12 months.

KMDA's P/E Growth Rating (40) in the Biotechnology industry is in the same range as RDY (54) in the Pharmaceuticals Generic industry. This means that KMDA’s stock grew similarly to RDY’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
KMDARDY
RSI
ODDS (%)
N/A
Bearish Trend 3 days ago
64%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
68%
Bullish Trend 3 days ago
50%
Momentum
ODDS (%)
Bearish Trend 3 days ago
68%
Bearish Trend 3 days ago
53%
MACD
ODDS (%)
Bearish Trend 3 days ago
60%
Bearish Trend 3 days ago
59%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
66%
Bearish Trend 3 days ago
53%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
66%
Bullish Trend 3 days ago
45%
Advances
ODDS (%)
Bullish Trend 21 days ago
65%
Bullish Trend 12 days ago
49%
Declines
ODDS (%)
Bearish Trend 3 days ago
65%
Bearish Trend 4 days ago
54%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
77%
Bullish Trend 3 days ago
58%
Aroon
ODDS (%)
Bearish Trend 3 days ago
60%
Bullish Trend 3 days ago
43%
View a ticker or compare two or three
Interact to see
Advertisement
KMDA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RDY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
DTEGF33.670.27
+0.79%
Deutsche Telekom AG
FBPI11.60N/A
N/A
First Bancorp of Indiana, Inc.
GIFLF13.90N/A
N/A
Grifols Sa
HKTVY3.69N/A
N/A
Hong Kong Technology Venture Company Ltd
MNHFF72.00N/A
N/A
Mayr-Melnhof Karton AG

KMDA and

Correlation & Price change

A.I.dvisor tells us that KMDA and SIGA have been poorly correlated (+27% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that KMDA and SIGA's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To KMDA
1D Price
Change %
KMDA100%
-0.30%
SIGA - KMDA
27%
Poorly correlated
+4.33%
OGI - KMDA
26%
Poorly correlated
-3.43%
SCYX - KMDA
23%
Poorly correlated
-0.46%
PAHC - KMDA
23%
Poorly correlated
+2.02%
RDY - KMDA
23%
Poorly correlated
+0.42%
More

RDY and

Correlation & Price change

A.I.dvisor tells us that RDY and HROW have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that RDY and HROW's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RDY
1D Price
Change %
RDY100%
+0.42%
HROW - RDY
29%
Poorly correlated
+2.06%
COLL - RDY
29%
Poorly correlated
-0.69%
AVDL - RDY
27%
Poorly correlated
+0.07%
VTRS - RDY
27%
Poorly correlated
+0.32%
TAK - RDY
25%
Poorly correlated
+0.61%
More